Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. - Wikidata - awgldk - TriplyDB

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.

http://www.wikidata.org/entity/Q30409116

about

Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions Acute kidney injury: preclinical innovations, challenges, and opportunities for translation Hepatic Encephalopathy: From the Pathogenesis to the New Treatments.Management of Neurologic Manifestations in Patients with Liver Disease.Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options.Prospective Multicenter Observational Study of Overt Hepatic Encephalopathy.Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary.Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France.Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients Useful tests for hepatic encephalopathy in clinical practice.Managing complications in cirrhotic patients Clinical science workshop: targeting the gut-liver-brain axis.Hepatic encephalopathy: a critical current review.Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy.An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease.Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.The Pharmabiotic Approach to Treat Hyperammonemia.Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy?Phenylbutyrate exerts adverse effects on liver regeneration and amino acid concentrations in partially hepatectomized rats.Where are we going? Translational research in hepatic encephalopathy.Hypothesis: Role for ammonia neutralization in the prevention and reversal of heart failure.Hepatic encephalopathy: current challenges and future prospects.Update on the Therapeutic Management of Hepatic Encephalopathy.Hepatic encephalopathy

P2860

Q26744689-DD1C58A6-F3B2-4F71-BCD3-D6C35C1B6F2A Q26786667-1347074F-E3F2-45FB-8CC4-167344ECF095 Q30381016-96111DC7-AEE4-474D-95C4-79EDB0CE52DB Q31108752-79E211FD-D127-4B94-8341-AEFA4CCAAB7D Q33805285-34C07604-D164-4312-A4AD-F834A12277AC Q34509599-B6C412A3-3DE0-46BE-B7D6-4129E68FE2F1 Q34530153-7741873E-5A95-4B6C-8027-B4C07BD4F544 Q37019499-2F3699B8-902E-47F8-ABEE-C94825B9D495 Q37361451-5846AD2C-66B1-47DA-9A82-F7D974F99807 Q38172872-DD5CC4F7-1C7E-47BF-907F-9CC69887BC0F Q38344890-C3632B7B-39AA-4BF3-9DB4-080E713129CA Q38601692-184575E9-5BBA-4D05-A874-0272DCCDC3AC Q38645107-EADB4D9C-B3FA-4327-9A62-760CBC31F178 Q38835093-D69EA2BC-2686-44BE-8820-DE71431354C9 Q39012545-A33C3E8F-4CB6-4CEA-B430-66077AF1C985 Q39658369-043A51AD-26CE-40E3-A428-C732082AC9E2 Q47312982-F8D77F94-5F37-4D8A-A22C-CE34290A7D87 Q47831420-20720BB4-6485-48AC-8B27-FD8A0302DA54 Q48245085-7AB6A8AB-BB74-4EFB-8993-4773C94BF96F Q51661337-D0997845-C428-49AC-8F88-B88B002636E5 Q52149705-4E010698-25A0-4200-ADAB-53D5B93022AA Q52652520-55F9BAA9-258D-4D80-8855-5D9D298D2663 Q54243938-085A7293-D5CE-4BF1-95B0-29B09BE9B022 Q55312369-FFAC8E0D-E2F3-4038-84AD-D62DD85FFA57 Q56456330-EA15569A-E72E-48EA-AF63-A2CAB0CCB162

P2860

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.

http://www.wikidata.org/entity/Q30409116

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Randomized, double-blind, cont ...... ate in hepatic encephalopathy.

@ast

Randomized, double-blind, cont ...... ate in hepatic encephalopathy.

@en

type

label

Randomized, double-blind, cont ...... ate in hepatic encephalopathy.

@ast

Randomized, double-blind, cont ...... ate in hepatic encephalopathy.

@en

prefLabel

Randomized, double-blind, cont ...... ate in hepatic encephalopathy.

@ast

Randomized, double-blind, cont ...... ate in hepatic encephalopathy.

@en

P1433

Q30409116-EA7AD90B-EB70-44F6-B0D2-4268B9F7BAC0

P1476

Q30409116-4C48FB57-834D-4F21-8E9C-EB5A045E41FC

P2093

Q30409116-03F898BA-1FBC-4A9C-91F3-A3A253FF1619

Q30409116-07B9CADE-01E9-44E9-99A1-2B43DE9E3529

Q30409116-07D4325B-C50E-4E91-83C1-26667F6BFCF8

Q30409116-190E3508-3F93-474A-9BC8-E138CFF41648

Q30409116-191F8B1E-563F-4B55-A4F2-C4DE6004F05C

Q30409116-19F35023-AFF8-48B3-AF0C-ABCF3CE707DA

Q30409116-2BF2EAA1-19AC-49A5-8D2D-E4C557B20BD6

Q30409116-38EFD945-9B18-4ECC-B38E-2FBD8B3E12A2

Q30409116-3E8F3811-65AE-482D-B54B-39E1101253EA

Q30409116-4A88A98E-5324-4F37-8D16-7620E0F7200C

P2860

Q30409116-168EF088-56B8-4BF7-9BC6-990E0FB8D71F

Q30409116-1848AE64-A205-40D0-A1EE-E757F84941AC

Q30409116-22531D51-EDAB-49AE-82D3-B983DB75144F

Q30409116-27971CA4-687E-4D4D-B7BD-2709B5833E94

Q30409116-3DFED208-658A-4476-9E15-C75B868A7F24

Q30409116-4ADDDD5F-0758-4326-A755-6F20D7431442

Q30409116-780106E4-2C8C-427F-9973-2C0D9CB43CC4

Q30409116-7DF1A409-C195-4657-9049-FFE1751AECF8

Q30409116-98C7527C-08B0-4D3A-ACB2-A73FFAC52E61

Q30409116-E4EA812B-28DD-402C-ACD3-85C06B8E3273

P304

Q30409116-569BA233-6065-479E-B116-9D34F699DAB6

P31

Q30409116-34757B50-930A-4E03-971B-6EFA7CEEC35D

P356

Q30409116-FBF300C9-1E9A-4E02-9190-8727B3D45361

P407

Q30409116-AE540BD8-44D9-4998-9CE0-06D4E9D64297

P433

Q30409116-DC58323D-A3EF-4EDF-A95C-1FCB8613D930

P478

Q30409116-DB6E036B-4FFB-45DC-8739-CE0B0CD2CEE8

P50

Q30409116-6F1E418D-EBA9-4643-869F-8ED61DE77AFB

Q30409116-A691DCCE-5FE7-4BB4-8996-019A8F82B50B

Q30409116-E9BF6211-7202-4C9B-821C-094029437D60

P577

Q30409116-DBF545AC-5E04-4E09-9E63-374B8AFE26A5

P5875

Q30409116-C26EE656-EE50-401A-9491-4C46BD6F5BD8

P698

Q30409116-EBE16F98-DD1A-4E16-A3AB-B94F160EB481

P932

Q30409116-7FE71415-1664-4F03-AFC2-87096E839942

P356

P1433

P1476

Randomized, double-blind, cont ...... rate in hepatic encephalopathy

@en

P2093

Andrey Baranovsky

http://www.w3.org/2001/XMLSchema#string

Bruce F Scharschmidt

http://www.w3.org/2001/XMLSchema#string

Catherine Norris

http://www.w3.org/2001/XMLSchema#string

Dion Coakley

http://www.w3.org/2001/XMLSchema#string

Don C Rockey

http://www.w3.org/2001/XMLSchema#string

HALT-HE Study Group

http://www.w3.org/2001/XMLSchema#string

Iryna Klaryts'ka

http://www.w3.org/2001/XMLSchema#string

John M Vierling

http://www.w3.org/2001/XMLSchema#string

K Gautham Reddy

http://www.w3.org/2001/XMLSchema#string

K Rajender Reddy

http://www.w3.org/2001/XMLSchema#string

P2860

Rifaximin treatment in hepatic encephalopathy

Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.

Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.

Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate.

Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate.

Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.

Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement.

The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus.

Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake.

P304

1073-1083

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.26611

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Igor A Zupanets

Galyna Fadieienko

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262043808

http://www.w3.org/2001/XMLSchema#string

P698

23847109

http://www.w3.org/2001/XMLSchema#string

P932

4237123

http://www.w3.org/2001/XMLSchema#string